InVitae Corp (N:NVTA)

Nov 11, 2019 06:30 am ET
Invitae to Acquire Clear Genetics
SAN FRANCISCO, Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care. ...
Nov 08, 2019 04:59 pm ET
University of Vermont Health Network begins offering Genomic DNA Testing
BURLINGTON, Vt., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions. ...
Nov 06, 2019 03:05 pm ET
Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2019....
Nov 05, 2019 06:30 am ET
Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference
SALT LAKE CITY, Nov. 5, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that helps push forward the science and practice of genetics in patient care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence in the field of genetic counseling. ...
Oct 23, 2019 07:30 am ET
Invitae to announce third quarter 2019 financial results on November 6, 2019
SAN FRANCISCO, Oct. 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. ...
Oct 17, 2019 07:30 am ET
Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward
HOUSTON, Oct. 17, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting data showing the increasing utility of genetic information at the American Society of Human Genetics (ASHG) annual meeting this week, ranging from comprehensive screening for cancer patients, to appropriate clinical follow up for women using non-invasive prenatal screening, to the limitations of direct to consumer genetic screening health reports. ...
Sep 09, 2019 07:30 am ET
Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic cancer. Genetic testing is recommended by clinicians for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials. ...
Sep 06, 2019 07:00 am ET
Invitae Prices Upsized Offering of $300 Million of Convertible Senior Notes
SAN FRANCISCO, Sept. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) announced the pricing on September 5, 2019 of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the offering was increased from the previously announced offering size of $200.0 million. Invitae granted the initial purchasers of the notes a 13-day option to purchase up to an additional $50....
Sep 04, 2019 04:05 pm ET
Invitae Announces Proposed Offering of $200 Million of Convertible Senior Notes
SAN FRANCISCO, Sept. 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with the offering, Invitae expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $30.0 million principal amount of notes on the sam...
Aug 20, 2019 07:30 am ET
Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
Biogen Inc. (Nasdaq: BIIB) and Invitae Corporation (NYSE: NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA...
Aug 06, 2019 04:15 pm ET
Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume
SAN FRANCISCO, Aug. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2019. ...
Jul 24, 2019 07:30 am ET
Invitae Launches Detect Programs to Make it Easier for Patients to Get Genetic Testing for Prostate Cancer, Muscular Dystrophy and Heart Conditions
SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases. ...
Jul 23, 2019 07:30 am ET
Invitae to announce second quarter 2019 financial results on August 6, 2019
SAN FRANCISCO, July 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. ...
Jul 11, 2019 04:06 pm ET
Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients
SAN FRANCISCO, July 11, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Jungla Inc., a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of genetic and genomic tests. The combination is expected to further enhance Invitae's genetic...
Jun 27, 2019 02:00 pm ET
Capital Market Laboratories (CMLviz) Interviews Invitae’s CEO –Invitae’s Non-Invasive Prenatal Screening Tests Can be a 50% Gross Margin Business
In an interview with Capital Market Laboratories (CMLviz), chief executive officer of Invitae (NYSE:NVTA) Sean George had a clear message: Invitae will never be announcing M&A in an attempt to fill a drop-in revenue. The acquisition of Singular Bio...
Jun 12, 2019 08:30 am ET
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Invitae Corporation (NYSE: NVTA), a leader in medical genetics, today announced a partnership to provide genetic testing at no cost to patients th
May 29, 2019 08:00 am ET
Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to people who may have a UCD, including their family members. Horizon’s support of the UCD Genetic Testing Program facilitates the genetic tests and services offered and performed by Invitae.
May 22, 2019 07:30 am ET
Invitae to Present at the 2019 William Blair Growth Stock Conference
SAN FRANCISCO, May 22, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock Conference on Wednesday, June 5, 2019 at 2:40 p.m. Central / 12:40 p.m. Pacific in Chicago....
May 15, 2019 07:30 am ET
Invitae to Present at the UBS Global Healthcare Conference
SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2019 at 10:30 a.m. Eastern / 7:30 a.m. Pacific in New York City. ...
May 07, 2019 04:05 pm ET
Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year
SAN FRANCISCO, May 7, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced financial and operating results for the first quarter ended March 31, 2019. ...
May 03, 2019 07:30 am ET
New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients
SAN FRANCISCO, May 3, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present a study of more than 6,500 patients with uterine cancer showing that genetic testing provided more than 80 percent of patients with information that made them eligible for precision medicine therapies. The study also highlighted the importance of multigene panel testing versus traditional, limited approaches and was presented this week at the 2019 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting....
Apr 23, 2019 07:30 am ET
Invitae to announce first quarter 2019 financial results on May 7, 2019
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. ...
Apr 11, 2019 08:16 am ET
FH Foundation Expands FIND FH® to Speed Diagnosis of Individuals with Homozygous Familial Hypercholesterolemia
PASADENA, Calif., April 11, 2019 /PRNewswire/ -- Today, the FH Foundation announced the launch of the FIND HoFH program to identify individuals at risk for homozygous familial hypercholesterolemia (HoFH). The goal is to accelerate the diagnosis of this life-threatening condition. HoFH is a more severe form of familial hypercholesterolemia (FH), that can lead to heart disease, heart attacks and aortic valve disease in children and young adults. Individuals identified through the program will have the option to receive genetic counseling and confirmatory genetic testing through a collaboration...
Apr 02, 2019 07:30 am ET
Research Underscores Need for Updated Guidelines to Include Multigene Testing for Cancer Patients
SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present data from more than 113,000 patients that support updating genetic testing guidelines to include clear recommendations for multigene panel testing in patients with cancer. According to the study, patients with ovarian, breast, pancreatic, prostate and colorectal cancer with potentially actionable germline variants are being missed each year when clinicians adhere to guidelines that restrict testing to one or a few gene panels. ...
Mar 14, 2019 07:30 am ET
Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference
SAN FRANCISCO, March 14, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City. ...
Mar 07, 2019 07:30 am ET
Recent Analysis Shows Invitae, Check Point Software Technologies, Ebix, CenturyLink, Republic Services, and Costamare Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Check Point Software Technologies Ltd....
Mar 06, 2019 08:31 pm ET
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the exercise in full of the underwriters' option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.00 per share, in connection with Invitae's recently announced underwritten public offering of 9,000,000 shares of its common stock. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approxi...
Mar 05, 2019 07:19 pm ET
Invitae Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, March 5, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $171.0 million. The offering is expected to close on or about March 8, 2019, subject to customary closing conditions. In addition, Invitae has granted the underwriters a...
Mar 04, 2019 03:07 pm ET
Invitae Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, March 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other c...
Feb 26, 2019 06:30 am ET
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Invitae Corporation (NYSE: NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (NASDAQ: XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. Previously available to patients ages 2-4 years, the program will expand eligibility to make no-cost genetic testing available for healthcare pr...
Feb 19, 2019 03:05 pm ET
Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018
SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018.  ...
Feb 13, 2019 07:45 am ET
Recent Analysis Shows General Mills, Paycom Software, Invitae, Jagged Peak Energy, John B. Sanfilippo & Son, and Intrepid Potash Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of General Mills, Inc. (NYSE:GIS), Paycom Software, Inc. (NYSE:PAYC), Invitae...
Feb 13, 2019 06:30 am ET
Invitae to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 a.m. Eastern / 8:30 a.m. Pacific in New York City. ...
Feb 12, 2019 06:30 am ET
Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy
SAN FRANCISCO, Feb. 12, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced the addition of non-invasive prenatal screening (NIPS) to the company's comprehensive women's health genetic testing services, providing patients with easier access to affordable genetic testing in early pregnancy. In combination with the expanded carrier screening (ECS), Invitae now offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for patients who need it. The company made the announcement in conjuncti...
Feb 07, 2019 11:00 am ET
New Study Finds Disease-Causing Variants More Common in Men with Prostate Cancer Than Previously Thought
SAN FRANCISCO, Feb. 7, 2019 /PRNewswire/ -- The largest study to date on the genetics of prostate cancer has found that 17 percent of prostate cancer patients are born with genetic variants that can be associated with higher risk of various cancers. The study was published today in JAMA Oncology by researchers from Tulane Cancer Center and Invitae (NYSE: NVTA), a leading genetics company. In addition, the analysis found that guidelines for genetic testing at the time of the study missed a substantial number of patients, suggesting broader testing is warranted. ...
Jan 29, 2019 06:30 am ET
Invitae to announce fourth quarter and year-end 2018 financial results on February 19, 2019
SAN FRANCISCO, Jan. 29, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. ...
Jan 07, 2019 06:30 am ET
Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond
SAN FRANCISCO, Jan. 7, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, announced preliminary unaudited full-year 2018 results showing triple-digit growth driven by strong commercial execution, test menu expansion and the accelerating use of genetics in healthcare. ...
Dec 20, 2018 03:31 pm ET
Invitae to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific at the Westin St. Francis Hotel in San Francisco. ...
Dec 10, 2018 06:30 am ET
New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients
SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians and Invitae (NYSE: NVTA), one of the fastest growing genetics companies. The findings support broadening and simplifying current guidelines to ensure all breast cancer patients have access to genetic information to guide the...
Dec 04, 2018 08:15 am ET
Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation (NYSE:UTX), Walmart Inc. (NYSE:WMT),...
Nov 14, 2018 06:30 am ET
Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference
ATLANTA, Nov. 14, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, are presenting research at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that further underscores the frequency of medically actionable genetic variants and their utility in clinical care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence in the field of genetic counseling. ...
Nov 07, 2018 03:05 pm ET
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018
SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the third quarter ended September 30, 2018. Based on progress in the quarter, Invitae is raising its volume guidance from more than 275,000 samples to more than 285,000 samples and raising its revenue guidance from between $135 and $140 million to between $140 and $145 million in 2018. ...
Oct 29, 2018 07:30 am ET
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
SAN FRANCISCO, Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing at no cost to patients through the Alnylam Act® program for individuals who may carry gene mutations associated with primary hyperoxaluria, an ultra-rare genetic disorder affecting the kidneys that most often presents in childhood. ...
Oct 25, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Develo
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc....
Oct 24, 2018 07:30 am ET
Invitae to announce third quarter 2018 financial results on November 7, 2018
SAN FRANCISCO, Oct. 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. ...
Oct 17, 2018 07:30 am ET
Research shows high positive rate for risk of hereditary disease in study of proactive genetic health screening for healthy people
SAN DIEGO, Oct. 17, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, will present findings showing proactive genetic testing identifies medically significant findings for 16.5 percent of healthy individuals. The data add to a growing body of evidence showing expanding clinical genetic testing to people without identified risks could be beneficial....
Sep 18, 2018 07:30 am ET
Invitae to Present at the Ladenburg Thalmann 2018 Healthcare Conference
SAN FRANCISCO, Sept. 18, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. Eastern / 6:00 a.m. Pacific in New York City....
Sep 11, 2018 07:30 am ET
Invitae Appoints Chitra Nayak to its Board of Directors
SAN FRANCISCO, Sept. 11, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced the appointment of Chitra Nayak to its Board of Directors, effective September 10, 2018. ...
Sep 05, 2018 07:40 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Destination XL Group, Invitae, Federated National Holding, Bridge, QCR, and Kelly Services — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Destination XL Group, Inc. (NASDAQ:DXLG), Invitae Corporation (NYSE:NVTA),...
Aug 16, 2018 08:15 am ET
Investor Expectations to Drive Momentum within Global Medical REIT, Cyclacel Pharmaceuticals, Super Micro Computer, Kelly Services, Invitae, and ScanSource — Discovering Underlying Factors of Influenc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Global Medical REIT Inc. (NYSE:GMRE), Cyclacel Pharmaceuticals, Inc....
Aug 07, 2018 04:05 pm ET
Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018
SAN FRANCISCO, Aug. 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the second quarter ended June 30, 2018. Based on progress in the quarter, Invitae is raising its revenue guidance from more than $130 million to between $135 and $140 million in 2018. ...
Jul 24, 2018 07:30 am ET
Invitae to announce second quarter 2018 Financial Results on August 7, 2018
SAN FRANCISCO, July 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its second quarter 2018 financial results on Tuesday, August 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights....
Jun 25, 2018 07:30 am ET
Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening
SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the launch of the Invitae Carrier Screen, a comprehensive test designed to provide affordable, accessible information on genetic changes that pose a risk for parents of having a child with an inherited genetic disorder. Each year 7.8 million children worldwide are born with health problems caused at least in part by genetics1....
Jun 13, 2018 07:30 am ET
Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing
SAN FRANCISCO, June 13, 2018 /PRNewswire/ -- Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes, also called exonic copy number variants (CNVs), are present in a substantial number of patients and suggested that CNV testing should be universally used in clinical genetic testing. With few exceptions, these types of exonic CNVs are not typically dete...
May 30, 2018 07:30 am ET
Invitae to Present at the William Blair 2018 Growth Stock Conference
SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018 at 4:10 p.m. Central / 5:10 p.m. Eastern / 2:10 p.m. Pacific in Chicago. ...
May 09, 2018 04:05 pm ET
Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018
SAN FRANCISCO, May 9, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the first quarter ended March 31, 2018. Based on the growing momentum in test volume and substantial revenue growth, the company is increasing its volume guidance from accessioning 250,000 samples to accessioning more than 275,000 samples in 2018. Additionally, the company is raising its revenue guidance from at least $120 million to more than $130 million in 2018. ...
May 07, 2018 07:30 am ET
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
SAN FRANCISCO, May 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the expansion of its partnership with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) to assist clinicians in identifying patients with Duchenne muscular dystrophy (DMD).    ...
May 04, 2018 07:55 am ET
Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LRAD Corporation (NASDAQ:LRAD), Xencor, Inc. (NASDAQ:XNCR), QuinStreet,...
May 03, 2018 07:30 am ET
Invitae to participate in two upcoming investor conferences, the Bank of America Merrill Lynch 2018 Heath Care Conference and the UBS Global Healthcare Conference
SAN FRANCISCO, May 3, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will participate in two upcoming investor conferences:...
Apr 27, 2018 07:30 am ET
Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)
SAN FRANCISCO, April 27, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it is launching a new program with Biogen, a leading biotechnology company, to offer genetic testing at no charge to patients suspected of having or clinically diagnosed with spinal muscular atrophy (SMA), a rare, progressive, genetic, neuromuscular disease. The program, SMA Identified, is the latest addition to Invitae's network of partnerships that connect patients and clinicians to treatment and research....
Apr 25, 2018 07:30 am ET
Invitae to Announce First Quarter 2018 Financial Results on May 9, 2018
SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its first quarter 2018 financial results on Wednesday, May 9, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. ...
Apr 10, 2018 07:30 am ET
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing
CHARLOTTE, N.C., April 10, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present findings showing proactive genetic health screening reveals medically significant findings for a substantial portion of patients, and looking for secondary findings during genetic testing provides a substantial yield of actionable risk factors for disease. The studies are among the company's data being presented this week at the American College of Medical Genetics (ACMG) annual meeting in Charlotte, NC....
Mar 28, 2018 06:00 am ET
Invitae Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, March 28, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or about April 2, 2018, subject to customary closing conditions. In addition, Invita...
Mar 26, 2018 04:05 pm ET
Invitae Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, March 26, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other con...
Mar 22, 2018 07:30 am ET
Invitae expands network of patients in rare and ultra-rare diseases
SAN FRANCISCO, March 22, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced an expansion of its network of rare and ultra-rare patient registries in its Patient Insights NetworkTM (PIN) program to include five additional collaborations with leading advocacy groups across a variety of genetic conditions. The programs are designed to empower patients to be active participants in their networks and further expand Invitae's work to connect patients with rare genetic disorders to research, clinical trials and informatio...
Mar 19, 2018 08:00 am ET
Analysis: Positioning to Benefit within ICF International, Invitae, Encore Wire, Alexandria Real Estate Equities, Syndax Pharmaceuticals, and Vical — Research Highlights Growth, Revenue, and Consolida
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICF International, Inc. (NASDAQ:ICFI), Invitae Corporation...
Mar 16, 2018 07:30 am ET
Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information
SAN FRANCISCO, and CAMBRIDGE, Mass., March 16, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) and KEW, Inc. today announced a collaboration to develop comprehensive genomic profiling solutions for sequencing tumor DNA on Invitae's next generation sequencing (NGS) platform. By adding KEW's somatic mutation detection capabilities to Invitae's extensive portfolio of diagnostic genetic testing panels for hereditary cancers, Invitae will be able to help clinicians guide their patients from initial cancer diagnosis through treatment and monitoring. ...
Feb 27, 2018 03:05 pm ET
Invitae expands existing credit facility to provide up to $40.0 million in available growth capital
SAN FRANCISCO, Feb. 27, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has reached an agreement with Oxford Finance, LLC to expand its existing loan and security agreement by $20.0 million, bringing the total remaining capital available under the agreement to $40.0 million. This increase in net borrowing ability provides additional financial flexibility in 2018 as Invitae seeks to grow the size and scope of its genome network....
Feb 26, 2018 06:30 am ET
Invitae to present at the Cowen and Company 38th Annual Health Care Conference
SAN FRANCISCO, Feb. 26, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the Cowen and Company 38th Annual Health Care Conference  in Boston on Monday, March 12, 2018 at 11:20 a.m. Eastern / 8:20 a.m. Pacific in Boston, Massachusetts. ...
Feb 12, 2018 03:05 pm ET
Invitae reports over 150% volume and over 170% revenue growth for 2017
SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017....
Feb 12, 2018 12:00 pm ET
Invitae Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Invitae Corp. (NYSE: NVTA) will be discussing their earnings results in their Q4 Earnings Call to be held on February 12, 2018 at 4:30 PM Eastern Time.
Jan 31, 2018 06:30 am ET
Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference
SAN FRANCISCO, Jan. 31, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will participate in two upcoming investor conferences being held in New York City. ...
Jan 29, 2018 06:30 am ET
Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018
SAN FRANCISCO, Jan. 29, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2017 financial results on Monday, February 12, 2018 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. ...
Jan 09, 2018 07:45 am ET
Report: Exploring Fundamental Drivers Behind Invitae, MKS Instruments, YRC Worldwide, Hospitality Properties, Pioneer Energy Services, and Encore Wire — New Horizons, Emerging Trends, and Upcoming Dev
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), MKS Instruments, Inc....
Jan 08, 2018 06:30 am ET
Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018
SAN FRANCISCO, Jan. 8, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced preliminary full-year 2017 results that demonstrate continued strong momentum, with volume and revenue more than doubling compared to 2016 results. Preliminary financial results for 2017 include:...
Dec 20, 2017 06:30 am ET
Invitae to present at the 36th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Dec. 20, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 2:00 p.m. Pacific at The Westin St. Francis in San Francisco....
Nov 15, 2017 07:30 am ET
Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services
SAN FRANCISCO, Nov. 15, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has completed its acquisition of CombiMatrix, which specializes in providing genetic information for prenatal diagnosis, miscarriage analysis and diagnosis of pediatric developmental disorders, establishing Invitae as a new leader in family and reproductive genetic health services. ...
Nov 10, 2017 04:15 pm ET
CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation
IRVINE, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today that, based upon the final vote count for the Company’s Special Meeting of Stockholders held today, a majority of its stockholders voted to approve the previously announced merger agreement with Invitae Corporation (NYSE:NVTA) (“Invitae”), pursuant to which the Company would become a wholly owned subsidiary of Invitae upon closing of ...
Nov 10, 2017 04:15 pm ET
CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation
IRVINE, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today that, based upon the final vote...
Nov 08, 2017 04:38 pm ET
Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F Warrants
SAN FRANCISCO, Nov. 8, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) one of the fastest growing genetic information companies, today issued a reminder to CombiMatrix Corporation Series F warrant holders regarding the previously announced offer to exchange (the "Exchange Offer") each outstanding Series F warrant (CUSIP No. 20009T147) (the "CombiMatrix Series F warrants") to acquire one share of common stock of CombiMatrix Corporation ("CombiMatrix") for 0.3056 of a share of common stock, par value $0.0001 per share, of Invitae (the "Invitae Common Stock").  All of the previousl...
Nov 06, 2017 04:01 pm ET
Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017
SAN FRANCISCO, Nov. 6, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended September 30, 2017, including continued business momentum, double-digit sequential volume and revenue growth, and a strengthened financial position. ...
Oct 30, 2017 08:30 am ET
Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage
SAN ANTONIO, Oct. 30, 2017 /PRNewswire/ -- Invitae (NYSE: NVTA), one of the fastest growing genetic information companies, is presenting validation data for a novel, NGS-based preimplantation genetic screening (PGS) technology that accurately identifies certain chromosomal abnormalities potentially missed on other PGS platforms. In addition, company researchers are sharing data suggesting that if initial PGS testing yields no results, a second biopsy may provide actionable information. These studies are among the seven being presented by researchers from Good Start Genetics, now part of Invi...
Oct 26, 2017 07:00 am ET
Safeguard Scientifics Announces Third Quarter 2017 Financial Results
RADNOR, Pa., Oct. 26, 2017 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE: SFE) ("the Company") today announced financial results for the three months and nine months ended September 30, 2017, as well as continued achievement of developmental milestones for its 26 partner companies. For the three months ended September 30, 2017, Safeguard's net loss was $18.7 million, or $0.91 per share, compared with net loss of $24.1 million, or $1.18 per share, for the same period in 2016. For the nine months ended September 30, 2017, the Company's net loss was $69.8 million, or $3.42 per share, compar...
Oct 24, 2017 08:30 am ET
Invitae to announce third quarter 2017 Financial Results and Host Conference Call on November 6, 2017
SAN FRANCISCO, Oct. 24, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its third quarter 2017 financial results on Monday, November 6, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. ...
Oct 17, 2017 08:30 am ET
Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection
SAN FRANCISCO, Oct. 17, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, is presenting data showing genetic sequencing and copy number variant (CNV) detection performed together using expert-curated panels offers better diagnosis rates over sequencing alone in patients with neuromuscular disorders and childhood epilepsy. The studies are among the company's 15 posters and presentations at the 2017 American Society of Human Genetics (ASHG) Annual Meeting in Orlando. ...
Oct 06, 2017 08:30 am ET
Invitae Commences Exchange Offer for CombiMatrix Series F Warrants
SAN FRANCISCO, Oct. 6, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has commenced an offer to exchange (the "Exchange Offer") each outstanding Series F warrant (CUSIP No. 20009T147) (the "CombiMatrix Series F Warrants") to acquire one share of common stock of CombiMatrix Corporation ("CombiMatrix") for 0.3056 of a share of common stock, par value $0.0001 per share, of Invitae (the "Invitae Common Stock")....
Oct 05, 2017 08:30 am ET
Invitae's new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide
SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ -- As genetic testing grows both more complex and more integrated into mainstream medical care, continually improving how genetic variants are classified as pathogenic, benign or unknown is essential. Researchers with Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, have developed and validated a new framework that refines genetic variant classification guidelines, resulting in a more complete and consistent approach that can be reproduced across genetic testing laboratories. Featured in the October print iss...
Sep 13, 2017 08:35 am ET
Invitae highlighting new research, expanded suite of services at National Society of Genetic Counselors (NSGC) 36th Annual Conference
COLUMBUS, Ohio, Sept. 13, 2017 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present initial findings showing proactive genetic health screening revealed medically significant findings for nearly one in five patients in a study presented at the National Society of Genetic Counselors (NSGC) 36th Annual Conference. The company will also unveil a new software platform to help genetic counselors gather and manage family history and patient information essential for clinical decision making. The information is amo...
Sep 13, 2017 08:30 am ET
Invitae to Present at the Cantor Fitzgerald Global Healthcare Conference
SAN FRANCISCO, Sept. 13, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Katherine Stueland, chief commercial officer of Invitae, will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at approximately 11:30 a.m. Eastern / 8:30 a.m. Pacific in New York City. ...
Aug 29, 2017 08:30 am ET
Invitae to Participate in the Morgan Stanley 15th Annual Global Healthcare Conference
SAN FRANCISCO, Aug. 29, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference on Monday, September 11, 2017 at approximately 3:40 p.m. Eastern / 12:40 p.m. Pacific in New York City. ...
Aug 07, 2017 05:05 pm ET
Invitae Reports Second Quarter 2017 Results
SAN FRANCISCO, Aug. 7, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended June 30, 2017. ...
Jul 31, 2017 06:15 pm ET
Safeguard Scientifics Partner Company Good Start Genetics To Be Acquired By Invitae Corporation
RADNOR, Pa., July 31, 2017 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE:SFE) today announced that its partner company, Good Start Genetics, Inc. ("Good Start"), signed a definitive agreement to be acquired by San Francisco-based genetics information company, Invitae Corporation (NYSE:NVTA). The transaction is expected to close in the first part of August 2017, subject to customary closing conditions. Safeguard expects to receive initial consideration consisting of $3.8 million of Invitae common stock, based on the 30-day trailing average stock price, and an additional $1.3 million of In...
Jul 31, 2017 05:57 pm ET
Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life
SAN FRANCISCO, July 31, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced two acquisitions to establish a leading position in family health genetic information services. Invitae has entered into a definitive agreement to acquire privately held Good Start Genetics, a molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders. Invitae also has entered into a definitive agreement to acquire CombiMatrix (NASDAQ: CBMX), a company which specializes in prenatal diagnosis, misca...
Jul 31, 2017 05:54 pm ET
Invitae Announces $73.5 Million Private Placement Offering to Fuel Strategic Growth Opportunities and Reports Preliminary Second Quarter Financial Results
SAN FRANCISCO, July 31, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has entered into a definitive agreement to sell $73.5 million of Invitae stock in a private placement. The private placement is being led by existing investors with significant participation from multiple new investors. The placement is expected to provide Invitae with added resources and flexibility as it builds a comprehensive offering to accelerate the use of genetic information in mainstream medical care....
Jul 31, 2017 04:58 pm ET
CombiMatrix Enters Into Merger Agreement with Invitae Corporation to be Acquired for $33 Million in Invitae Common Stock
$27 million offered to holders of CombiMatrix Common Stock (Nasdaq: CBMX) subject to certain adjustments...
Jul 24, 2017 08:30 am ET
Invitae to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 7, 2017
SAN FRANCISCO, July 24, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its second quarter 2017 financial results on Monday, August 7, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. ...
Jun 12, 2017 08:30 am ET
Invitae Acquires CancerGene Connect, Award-Winning Risk Assessment and Family History Analysis Platform
SAN FRANCISCO, June 12, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has acquired Ommdom Inc., which develops healthcare software, including CancerGene Connect, one of the most efficient, end-to-end platforms available for collecting and managing genetic family histories. The acquisition expands the company's suite of genome management offerings designed to help patients and clinicians use genetic information as part of mainstream medical care....
Jun 05, 2017 09:17 am ET
ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines
CHICAGO, June 5, 2017 /PRNewswire/ -- A new analysis of genetic testing results among prostate cancer patients shows a substantial portion of patients with clinically significant genetic variants will be missed under current testing guidelines. These data add to the evidence supporting the re-evaluation of germline genetic testing guidelines for prostate cancer patients. The study was presented by a team including researchers from Invitae Corporation (NYSE: NVTA) and the Tulane University School of Medicine at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, where...
Jun 01, 2017 10:08 am ET
Invitae to present at the Goldman Sachs 38th Annual Global Healthcare Conference
SAN FRANCISCO, June 1, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Randy Scott, executive chairman of Invitae, will present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15, 2017 at 8:40 a.m. Pacific at the Terranea Resort in Rancho Palos Verdes, California. ...
May 25, 2017 08:30 am ET
Invitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand
SAN FRANCISCO, May 25, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced that industry veteran Shelly Guyer, most recently chief financial officer at Veracyte, Inc., a genomic diagnostics company, has been named chief financial officer, effective June 12, 2017. Upon her appointment, Invitae's current chief financial officer, Lee Bendekgey, will fully transition to the role of chief operating officer....
May 12, 2017 08:30 am ET
Invitae to Present at the UBS Global Healthcare Conference
SAN FRANCISCO, May 12, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Monday, May 22, 2017 at 11:00 a.m. Eastern / 8:00 a.m. Pacific in New York City. ...
May 08, 2017 05:01 pm ET
Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017
SAN FRANCISCO, May 8, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended March 31, 2017. ...
Apr 28, 2017 08:30 am ET
New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing
LAS VEGAS, April 28, 2017 /PRNewswire/ -- New research suggests that current clinical guidelines on the use of genetic testing in breast cancer patients are too narrow and allow patients with pathogenic variants to be missed. The findings were presented at the American Society of Breast Surgeons (ASBS) Annual Meeting in Las Vegas, and come from a collaboration between TME Research, which represents more than 300 breast care practices in the United States, and Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies....
Apr 27, 2017 08:30 am ET
Invitae to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
SAN FRANCISCO, April 27, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer, will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Thursday, May 18, 2017 at 10:40 a.m. Pacific in Las Vegas. Sean George will also participate in a panel discussion titled "Genetic Testing - Pricing, Payment and Policy in a Rapidly Growing Space" on Wednesday, May 17 at 4:20 p.m. Pacific. ...
Apr 24, 2017 08:30 am ET
Invitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017
SAN FRANCISCO, April 24, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its first quarter 2017 financial results on Monday, May 8, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. ...
Apr 20, 2017 08:30 am ET
Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested
SAN FRANCISCO, April 20, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the addition of 80 new panels alongside updates to an additional 24 panels for the diagnosis of inherited immunologic and metabolic disorders, including panels designed to confirm diagnoses suggested by newborn screening. The new and updated tests further expand the company's robust menu of high-quality, affordable diagnostic genetic tests available for use by clinicians. ...
Apr 06, 2017 10:00 am ET
Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to research
SAN FRANCISCO, April 6, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the launch of the Invitae Patient Insights Network℠, a permission-based, patient-centered network designed to make it easy for patients to share health experiences, contribute de-identified clinical data, and maintain their privacy while being connected to the latest research, treatment, and disease education opportunities. ...
Apr 03, 2017 08:30 am ET
Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis
SAN FRANCISCO, April 3, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has announced a program in partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing for hereditary ATTR (hATTR) amyloidosis, a rare, progressive and life-threatening disease caused by a mutation in the TTR gene which causes accumulation of misfolded proteins in nerves and cells of other organs. ...
Mar 30, 2017 08:30 am ET
Invitae announces introduction of exome testing
SAN FRANCISCO, March 30, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced a major expansion of its genetic testing services with the introduction of exome sequencing and interpretation services, bringing the company's available test menu to more than 20,000 genes. The Invitae Boosted Exome offers high-quality testing tailored to each patient's unique clinical situation. Exome testing can help clinicians make or confirm a diagnosis and develop an appropriate medical management plan,which is especially important in...
Mar 23, 2017 08:30 am ET
Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults
SAN FRANCISCO, March 23, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has expanded the menu of tests offered as part of its ongoing proactive genetic testing pilot program. The announcement was made during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix, where Invitae researchers also presented findings from the company's growing body of experience on the use of proactive testing. ...
Mar 22, 2017 08:30 am ET
Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
SAN FRANCISCO, March 22, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the availability of a new genetic test for the diagnosis of Spinal Muscular Atrophy (SMA), a neuromuscular disease that is one of the leading lethal genetic disorders among infants as well as a significant cause of progressive neuromuscular disease in childhood. The new test, announced during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, features a novel, custom methodology that offers significant improve...
Mar 14, 2017 08:30 am ET
Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting
SAN FRANCISCO, March 14, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it will be presenting seventeen posters and presentations at the 2017 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix. ...
Feb 21, 2017 11:07 am ET
Invitae to present at the Cowen and Company 37th Annual Health Care Conference
SAN FRANCISCO, Feb. 21, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that members of the company's management team will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 at approximately 4:00 p.m. Eastern / 1:00 p.m. Pacific in Boston, Massachusetts. ...
Feb 17, 2017 07:30 am ET
New research suggests broader genetic testing of prostate cancer patients may be warranted to identify risk of an inherited mutation that might inform treatment
ORLANDO, Fla., Feb. 17, 2017 /PRNewswire/ -- New research suggests that a substantial fraction of patients with prostate cancer and a positive family history are at high risk of an inherited genetic mutation that might help inform their treatment options. Among those men with prostate cancer meeting NCCN guidelines for testing, these initial data support the concept that particulars in the family history cannot be used to predict pathogenic variants. ...
Jan 30, 2017 07:30 am ET
Invitae to announce fourth quarter and year-end 2016 financial results and 2017 guidance and will host conference call on February 13, 2017
SAN FRANCISCO, Jan. 30, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2016 financial results and provide 2017 guidance on Monday, February 13, 2017, and Invitae's management team will host a conference call that day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ...
Jan 09, 2017 07:30 am ET
Invitae announces new leadership structure to drive global growth
SAN FRANCISCO, Jan. 9, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, Ph.D., its co-founder and current president and chief operating officer, has been named chief executive officer for the company. Current chairman and chief executive officer Randy Scott will become executive chairman of the board of directors and remain full time at the company. The appointments are effective immediately....
Jan 06, 2017 07:05 am ET
Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data company
SAN FRANCISCO, Jan. 6, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced initial fourth quarter and full-year 2016 results, showing 200% year-over-year growth in billable test volume, driven by milestones including a major expansion of its test menu to more than 1,100 genes and agreements with the nation's largest payers to provide coverage for more than 175 million lives in aggregate.  ...
Jan 06, 2017 07:00 am ET
Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseases
SAN FRANCISCO, Jan. 6, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has acquired AltaVoice (formerly PatientCrossroads), a privately owned, patient-centered data company with a global platform for collecting, curating, coordinating, and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other unique partnerships, expands Invitae's Genome Network, designed to connect patients, clinicians, advocacy organizations, researchers, and therapeutic developers to accel...
Dec 28, 2016 07:27 am ET
Invitae to present at the 35th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Dec. 28, 2016 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that members of the company's management team will present at the 35th Annual J.P. Morgan Healthcare conference on Wednesday, January 11, 2017 at 2:30 p.m. Pacific at The Westin St. Francis in San Francisco. ...
Dec 21, 2016 07:27 am ET
Invitae announces major expansion of its pediatric, neurological, and rare disease genetic test offerings
SAN FRANCISCO, Dec. 21, 2016 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the availability of 24 new and 19 expanded genetic test panels, allowing clinicians to gain information on 183 new genes with clinical and diagnostic significance. This launch represents a significant expansion of the company's pediatric, neurological,and rare disease offerings, which include tests for genes associated with epilepsy, developmental disorders, overgrowth syndromes, and skeletal disorders, as well as tests in dermatology, immunology, and ophthalmology....